Join
Live feed
·
PRReleasevia Quantisnow
Opus Genetics Inc. logo

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

ByQuantisnow·Wall Street's wire, on your screen.
IRD· Opus Genetics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IRD (Opus Genetics Inc.) and more on Quantisnow.